Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up - 26/03/08
Cécile Poupardin [1],
Marc Lémann [2],
Jean-Pierre Gendre [3],
Jean-Marc Sabaté [1],
Philippe Marteau [4],
Stanislas Chaussade [5],
Jean-Charles Delchier [6],
Yoram Bouhnik [7],
Jean-Claude Chaput [8],
Raoul Poupon [9],
Jean-Claude Soulé [10],
Yves Benhamou [11],
Jean-Didier Grangé [12],
Benoît Coffin [1]
Voir les affiliations
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Objectives |
To evaluate prescription practices and response to infliximab treatment for Crohn's disease (CD).
Patients and methods |
The files of CD patients treated with at least one infusion of infliximab treated in gastroenterology units belonging to university teaching hospitals of the Parisian hospitals group (Assistance Publique-Hôpitaux de Paris (AP-HP) during the year 2000 were analyzed retrospectively.
Results |
One hundred and thirty-seven patients (36.0 ± 12.7 years, 92 females) from 12 centers were studied. Indication for treatment was fistulae or perianal disease in 39% of patients, active Crohn's disease in 45% and mixed conditions in 16%. Mean follow-up was 15.2 ± 7.2 months. The overall response rate was 85%. No predictive factor of sustained remission could be identified. The mean time to relapse was to 3.9 ± 3.1 months. Thirty-eight patients were on maintenance therapy at the end of the follow up; 37% exhibiting progressive lost of response to treatment. Immunosuppressive therapy was added to infliximab in 78% of cases but response to infliximab was not modified by addition of immunosuppressive drugs. Adverse events, most frequently minor, were noted in 23% of the patients.
Conclusion |
This retrospective study confirms the efficacy and safety of infliximab in CD.
Plan
© 2006 Elsevier Masson SAS. Tous droits réservés.
Vol 30 - N° 2
P. 247-252 - février 2006 Retour au numéro
Article précédent
- Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL)
- Michel Amouretti, Claude Le Pen, Anne-Françoise Gaudin, Gilles Bommelaer, Jacques Frexinos, Philippe Ruszniewski, Thierry Poynard, Frédérique Maurel, Gaël Priol, Abdelkader El Hasnaoui
- Traitements palliatifs endoscopiques des cancers de l'œsophage
- Laetitia Dahan, Pauline Ries, René Laugier, Jean-François Seitz
Bienvenue sur EM-consulte, la référence des professionnels de santé.